RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Revenue of RedHill Biopharma Ltd. (RDHL)
Revenue in 2023 (TTM): $6.51 M
According to RedHill Biopharma Ltd.'s latest financial reports the company's current revenue (TTM) is $6.51 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of RedHill Biopharma Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $6.51 M | $3.05 M | $26.31 M | $23.95 M | $23.92 M |
| 2022 | $61.8 M | $28.46 M | $-42,844,000 | $-71,669,000 | $-59,245,000 |
| 2021 | $85.76 M | $36.35 M | $-63,028,000 | $-97,744,000 | $-114,311,000 |
| 2020 | $64.36 M | $27.47 M | $-54,939,000 | $-76,173,000 | $-89,017,000 |
| 2019 | $6.29 M | $4.03 M | $-40,784,538 | $-42,304,000 | $-43,634,000 |
| 2018 | $8.36 M | $5.52 M | $-38,604,159 | $-38,820,000 | $-38,820,000 |
| 2017 | $4.01 M | $1.88 M | $-45,785,104 | $-45,544,000 | $-45,544,000 |
| 2016 | $101 K | $-30,442,000 | $-30,499,000 | $-29,370,000 | $-29,370,000 |
| 2015 | $3 K | $-21,999,000 | $-21,866,000 | $-21,090,000 | $-21,090,000 |
| 2014 | $7.01 M | $5.96 M | $-10,620,000 | $-10,711,000 | $-10,711,000 |
| 2013 | $12 K | $12 K | $-10,748,000 | $-10,628,000 | $-10,628,000 |
| 2012 | $16 K | $16 K | $-9,016,000 | $-10,326,000 | $-10,326,000 |
| 2011 | $23 K | $23 K | $-7,858,000 | $-15,503,000 | $-15,503,000 |
| 2010 | $ | $ | $-2,548,347 | $-2,544,000 | $-2,544,000 |